EHA 2021 | The current and future ADC treatment landscape for lymphoma
Nilanjan Ghosh MD, PhD, Levine Cancer Institute, Charlotte, NC, gives an overview of antibody-drug conjugates (ADCs) for the treatment of lymphoma, describing their mechanism of action and discussing key developments. Three ADCs are currently approved for the treatment of lymphoma: brentuximab vedotin, polatuzumab vedotin and loncastuximab tesirine. Dr Ghosh talks on the approval of each of these immunotherapies and comments on their positioning in the lymphoma treatment landscape, as well as outlining the next steps and future research on the potential benefits of ADCs for patients with lymphoma. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Nilanjan Ghosh MD, PhD, has received personal fees for consulting or speakers bureau from AstraZeneca, Gilead/Kite, Janssen, Abbvie, Pharmacyclics, Genmab, Karyopharma, ADC Therapeutics, Adaptive Biotechnologies, Epizyme, Incyte, Bristol Myers Squibb and TG Therapeutics; and has received grant support from Genentech/Roche.
